Ocrelizumab and its role in the treatment of multiple sclerosis: A systematic review of the literature

Abstract

Introduction: Multiple Sclerosis is an autoimmune, chronic, progressive disease of the central nervous system that affects the myelin sheaths, producing a dysfunction in the nerve impulse, it is one of the main causes of neurological disability in young adults. Unfortunately, there is no cure for this disease, but there are many treatments to mitigate the outbreaks and progression of the disease. One of the promising drugs is ocrelizumab, a humanized monoclonal antibody against the CD20 antigen of B cells that has recently been approved by the US (Food and Drug Administration) and European (European Medicines Agency) health agencies for the treatment of sclerosis. multiplex (MS) and is the first drug to be marketed for both relapsingremitting MS (RRMS) and primary progressive MS (PPMS). Material and methods: A bibliographic search will be carried out in the different scientific databases, in order to investigate the role of ocrelizumab in the treatment of Multiple Sclerosis. Conclusion: MS is a disease that so far has no cure; however, a wide range of treatments are available that must be chosen according to the patient and his need. Within the vast range of treatment arises monoclonal antibodies that are specialized glycoproteins that are part of the immune system, produced by B cells, with the ability to recognize specific molecules (antigens). They are among the most promising agents for the treatment of MS. The most Used is ocrelizumab.